- Home
- WKSP vs TENX Comparison
WKSP vs TENX Comparison
Compare WKSP & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKSP
- TENX
- Stock Information
- Founded
- WKSP 2003
- TENX 1967
- Country
- WKSP United States
- TENX United States
- Employees
- WKSP N/A
- TENX N/A
- Industry
- WKSP Auto Parts:O.E.M.
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- WKSP Consumer Discretionary
- TENX Health Care
- Exchange
- WKSP Nasdaq
- TENX Nasdaq
- Market Cap
- WKSP 21.3M
- TENX 19.5M
- IPO Year
- WKSP N/A
- TENX N/A
- Fundamental
- Price
- WKSP $0.95
- TENX $5.52
- Analyst Decision
- WKSP
- TENX Strong Buy
- Analyst Count
- WKSP 0
- TENX 4
- Target Price
- WKSP N/A
- TENX $20.67
- AVG Volume (30 Days)
- WKSP 2.8M
- TENX 67.4K
- Earning Date
- WKSP 11-13-2024
- TENX 11-13-2024
- Dividend Yield
- WKSP N/A
- TENX N/A
- EPS Growth
- WKSP N/A
- TENX N/A
- EPS
- WKSP N/A
- TENX N/A
- Revenue
- WKSP $6,395,908.00
- TENX N/A
- Revenue This Year
- WKSP $366.78
- TENX N/A
- Revenue Next Year
- WKSP $311.43
- TENX N/A
- P/E Ratio
- WKSP N/A
- TENX N/A
- Revenue Growth
- WKSP 776.97
- TENX N/A
- 52 Week Low
- WKSP $0.36
- TENX $2.77
- 52 Week High
- WKSP $1.66
- TENX $27.36
- Technical
- Relative Strength Index (RSI)
- WKSP 62.36
- TENX 52.17
- Support Level
- WKSP $0.78
- TENX $5.70
- Resistance Level
- WKSP $1.09
- TENX $6.01
- Average True Range (ATR)
- WKSP 0.11
- TENX 0.48
- MACD
- WKSP 0.03
- TENX -0.06
- Stochastic Oscillator
- WKSP 69.11
- TENX 17.65
About WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.